Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12)

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 308-315

  Paul, Devchand ^a   Qazilbash, Muzaffar H ^a   Song, Kaimei ^a   Xu, Hui ^b   Sinha, Birandra K ^a   Liu, Johnson ^c   Cowan, Kenneth H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Adeno associated virus; Gene transfer; Interleukin 12 vector

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE INSERTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; ENCEPHALOMYOCARDITIS VIRUS; HUMAN ADENOVIRUS TYPE 5; MURINAE; ROUS SARCOMA VIRUS; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0034031750     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700105     Document Type: Article

References (59)

1. Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA. 1990;87:6808-6812.
2. Podlaski FJ, Nanduri VB, Hulmes JD, et al. Molecular characterization of interleukin 12. Arch Biochem Biophys. 1992;294:230-237.
3. Gately MK, Wilson DE, Wong HL. Synergy between recombinant IL-2 and IL-2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol. 1986;136; 1274-1282.
4. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827-845.
5. Wong HL, Wilson DE, Jenson JC, Familletti PC, Stremlo DL, Gately MK. Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol 1988;111:39-54.
6. + NK cells. J Immunol. 1992;148:2429-2436.
7. Kiniwa M, Gately M, Gubler U, Chizzonite R, Fargeas C, Delespesse G. Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4-stimulated human lymphocytes. J Clin Invest. 1992;90:262-266.
8. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 (IL-12)) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993;177:1199-1204.
9. + T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260:547-549.
10. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature. 1996;382:174-177.
11. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 1995;2:96-106.
12. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9:532-562.
13. Schoenhaut DS, Chua AO, Wolitzky AG, et al. Cloning and expression of murine IL-12. J Immunol. 1992;148: 3433-3444.
14. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
15. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 1994;153: 1697-1706.
16. Zitvogel L, Tahara H, Cai Q, et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther. 1994; 5:1493-1506.
17. Tahara H, Zeh HR, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994;54:182-189.
18. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1996;7: 1995-2002.
19. Meko JB, Yim JH, Tsung K, Norton JA. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. 1995;55:4765-4770.
20. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 1995;154:6466-6474.
21. Martinotti A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CDS-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol. 1995;25:137-146.
22. Obana S, Miyazawa H, Hara E, et al. Induction of anti-tumor immunity by mouse tumor cells transfected with mouse interleukin-12 gene. Jpn J Med Sci Biol. 1995;48:221-236.
23. Zitvogel L, Couderc B, Mayordomo JI, Robbins PD, Lotze MT, Storkus WJ. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann NY Acad Sci. 1996;795:284-293.
24. Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA. 1996;93:6291-6296.
25. Nishimura T, Watanabe K, Yahata T, et al. Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother Pharmacol. 1996;38:S27-S34.
26. Caruso M, Pham-Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA. 1996;93:11302-11306.
27. Rakhmilevich AL, Janssen K, Turner J, Culp J, Yang NS. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther. 1997;8:1303-1311.
28. Chen L, Chen D, Block E, O'Donnell M, Kufe DW, Clinton SK. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol. 1997;159:351-359.
29. Schmitt M, Ikeda H, Nagata Y, et al. Involvement of T-cell subsets and natural killer (NK) cells in the growth suppression of murine fibrosarcoma cells transfected with interleukin-12 (IL-12) genes. Int J Cancer. 1997;72:505-511.
30. Lieu FH, Hawley TS, Fong AZ, Hawley RG. Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy. Cancer Gene Ther. 1997;4:167-175.
31. Lieschke GJ, Rao PK, Gately MK, Mulligan RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol. 1997;15: 35-40.
32. Myers JN, Mank-Seymour A, Zitvogel L, et al. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope. 1998;108:261-268.
33. Lee YL, Tao MH, Chow YH, Chiang BL. Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy. Hum Gene Ther. 1998;9:457-465.
34. Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA. 1998;95:2475-2480.
35. Mu J, Zou JP, Yamamoto N, et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 1995;55:4404-4408.
36. Hoshino T, Jiang YZ, Dunn D, et al. Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: implications for tumor vaccination. Cancer Gene Ther. 1998;5:150-157.
37. Fujiwara H, Clark SC, Hamaoka T. Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Ann NY Acad Sci. 1996;795:294-309.
38. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol. 1996;106:1114-1118.
39. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 1996;87:3877-3882.
40. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581-586.
41. Shurin MR, Esche C, Peron JM, Lotze MT. Antitumor activities of IL-12 and mechanisms of action. Chem Immunol 1997;68:153-174.
42. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther. 1995;6:1607-1624.
43. Xiao X, Li J, McCown TJ, Samulski RJ. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol. 1997;144:113-124.
44. Xiao X, Li J, Samulski RJ. Production of high-liter recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72:2224-2232.
45. Chatterjee S, Wong K Jr. Adeno-associated virus vectors for gene therapy of the hematopoietic system. Curr Top Microbiol Immunol. 1996;218:61-73.
46. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70:8098-8108.
47. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. 1983;45:555-564.
48. Wang XS, Ponnazhagan S, Srivastava A. Rescue and replication signals of the adeno-associated virus 2 genome. J Mol Biol. 1995;250:573-580.
49. Wang XS, Ponnazhagan S, Srivastava A. Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J Virol. 1996;70:1668-1677.
50. Berns KI, Giraud C. Biology of adeno-associated virus. Curr Top Microbiol Immunol. 1996;218:1-23.
51. Anderson R, Macdonald I, Corbett T, Hacking G, Lowdell MW, Prentice HG. Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum Gene Ther. 1997;8:1125-1135.
52. Walsh CE, Nienhuis AW, Samulski RJ, et al. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest. 1994;94:1440-1448.
53. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther. 1997; 4:675-682.
54. Rolling F, Samulski RJ. AAV as a viral vector for human gene therapy: generation of recombinant virus. Mol Biotechnol. 1995;3:9-15.
55. Xu H, Rizzo LV, Caspi RR. IL-12 induces growth of the IL-4-dependent CT4S line and has a synergistic effect on IL-4-induced CT4S proliferation. J Immunol Methods. 1995;181:245-251.
56. Lotze MT, Zitvogel L, Campbell R, et al. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann NY Acad Sci. 1996;795:440-454.
57. Lament AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today. 1996;17:214-217.
58. Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther. 1996;7:333-342.
59. Li Z, Rakar A, Katayose Y, et al. Efficacy of multiple administration of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. Gene Ther. 1998;5:605-613.